Soufflé Therapeutics
Soufflé Therapeutics develops targeted RNA medicines for patients with muscle disorders and heart failure.
$135MSeries B
ParticipantVV
Vida Ventures
Activity from announced rounds
Activity in this selectionSeries B
- Rounds participated in
- 3
- Confirmed lead rounds
- 0 2 roles undisclosed
- New companies
- 3 First participation on record · 0 follow-on
- Funding in participating rounds
- $337M 3 disclosed · full round size, not this investor’s share